What is PolyActiva?
PolyActiva is a clinical-stage biotechnology firm specializing in the development of innovative, biodegradable implants designed for sustained drug delivery. At the core of its operations is the Prezia Sustained Drug Delivery Technology platform, which enables precise, controlled medication release to improve patient outcomes in ophthalmic care, particularly for glaucoma. By focusing on long-term treatment efficacy, the company addresses the significant burden of daily medication adherence in chronic disease management. Recent Phase 2 clinical data has validated the platform's ability to achieve meaningful reductions in intraocular pressure, positioning PolyActiva as a high-potential player in the medical device and pharmaceutical intersection.
How much funding has PolyActiva raised?
PolyActiva has raised a total of $36.9M across 3 funding rounds:
Series A
$1.6M
Series B
$9.5M
Series C
$25.8M
Series A (2011): $1.6M, investors not publicly disclosed
Series B (2013): $9.5M led by Medical Research Commercialisation Fund (MRCF)
Series C (2025): $25.8M supported by NRFC and Brandon Capital
Key Investors in PolyActiva
NRFC
The National Reconstruction Fund Corporation is an Australian Government initiative providing debt and equity to transform key industries, including medical science and high-value manufacturing.
Brandon Capital
Brandon Capital Partners is a premier venture capital firm focused on the biomedical sector, supporting life science companies from seed stage through to global commercialization.
Medical Research Commercialisation Fund (MRCF)
The MRCF is a specialized life science investment fund dedicated to transforming biomedical research discoveries into medical products that enhance patient outcomes.
What's next for PolyActiva?
With the recent capital injection, PolyActiva is expected to prioritize the advancement of its clinical programs and the scaling of its manufacturing capabilities. The strategic focus will likely shift toward finalizing late-stage clinical trials and navigating the regulatory pathways required for market entry. As the company matures, the integration of its Prezia platform into standard clinical practice will be the primary driver of long-term value creation. Investors are closely monitoring the firm's ability to translate its scientific research into a scalable, commercially viable product that offers a superior quality of life for patients suffering from degenerative ophthalmic diseases.
See full PolyActiva company page
